Progestogen (medication)

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vanished user 0x8cSXE0x6 (talk | contribs) at 23:15, 1 September 2018. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This article is about progestogens as medications. For the role of progestogens as hormones, see Progestogen.
Progestogen (medication)
Drug class
Medroxyprogesterone acetate (Provera, Depo-Provera), a progesterone derivative and one of the most widely used progestins.
Class identifiers
SynonymsSynthetic progestogens
UseHormonal birth control, hormone therapy, gynecological disorders, fertility and pregnancy support, sex hormone suppression, others
ATC codeG03
Biological targetProgesterone receptors (PR-A, PR-B, PR-C)
Chemical classSteroids (pregnanes, norpregnanes, androstanes, estranes)
Clinical data
Drugs.comDrug Classes
External links
MeSHD011372
Legal status
In Wikidata

A progestin is a type of medication which is used most commonly in hormonal birth control and menopausal hormone therapy.[1] They can also be used in the treatment of gynecological conditions, to support fertility and pregnancy, to lower sex hormone levels for various purposes, and for other indications.[1] Progestins are used alone or in combination with estrogens.[1] They are available in a wide variety of formulations and for use by many different routes of administration.[1]

Side effects of progestins include menstrual irregularities, headaches, nausea, breast tenderness, mood changes, acne, increased hair growth, and changes in liver protein production among others.[1][2] Other side effects of progestins include an increased risk of breast cancer, cardiovascular disease, and blood clots.[2] At high dosages, progestins can cause low sex hormone levels and associated side effects like sexual dysfunction and an increased risk of bone fractures.[3]

Progestins are synthetic progestogens and have similar effects to those of the natural hormone progesterone.[1] They act as agonists of the progesterone receptor, and have important effects in the female reproductive system (uterus, cervix, and vagina), the breasts, and the brain.[1] In addition, many progestins also have other hormonal activities, such as androgenic, antiandrogenic, estrogenic, glucocorticoid, or antimineralocorticoid activity.[1] They also have antigonadotropic effects and at sufficiently high dosages can strongly suppress sex hormone production.[1] Progestins mediate their contraceptive effects both by inhibiting ovulation and by thickening cervical mucus, thereby preventing fertilization.[4][5] They have functional antiestrogenic effects in certain tissues like the endometrium, and this underlies their use in menopausal hormone therapy.[1]

Progestins were first introduced for medical use in 1939.[6][7][8] They started to be used in birth control in the 1950s.[6] Around 60 progestins have been marketed for clinical use in humans or use in veterinary medicine.[9][10][11][12][13] These progestins can be grouped into different classes and generations.[1][14][15] Progestins are available widely throughout the world and are used in all forms of hormonal birth control and in most menopausal hormone therapy regimens.[9][10][12][11][1]

Medical uses

Birth control

Progestins are used in a variety of different forms of hormonal birth control for women, including combined estrogen and progestogen forms like combined oral contraceptive pills, combined contraceptive patches, combined contraceptive vaginal rings, and combined injectable contraceptives; and progestogen-only forms like progestogen-only contraceptive pills ("mini-pills"), progestogen-only emergency contraceptive pills ("day-after pills"), progestogen-only contraceptive implants, progestogen-only intrauterine devices, progestogen-only contraceptive vaginal rings, and progestogen-only injectable contraceptives.[16][17][18][19]

Progestins mediate their contraceptive effects by multiple mechanisms, including prevention of ovulation via their antigonadotropic effects; thickening of cervical mucus, making the cervix largely impenetrable to sperm; preventing capacitation of sperm due to changes in cervical fluid, thereby making sperm unable to penetrate the ovum; and atrophic changes in the endometrium, making the endometrium unsuitable for implantation.[20][21][22][23] They may also decrease tubal motility and ciliary action.[23]

Combined androgen and progestogen birth control methods for men have been extensively studied but have yet to be approved or marketed.[24]

Hormone therapy

Progestins are commonly used as a component of menopausal hormone therapy in women to prevent endometrial hyperplasia and increased risk of endometrial cancer from unopposed estrogen therapy. They are also used in transgender hormone therapy, including in both feminizing hormone therapy for transgender women (e.g., cyproterone acetate and medroxyprogesterone acetate to help suppress testosterone levels) and masculinizing hormone therapy in transgender men (e.g., medroxyprogesterone acetate to help suppress menses).

Certain progestins, including megestrol acetate, medroxyprogesterone acetate, cyproterone acetate, and chlormadinone acetate have been used to reduce hot flashes in men with prostate cancer.[25][26][27]

Gynecological disorders

Progestins are used to treat gynecological disorders such as secondary amenorrhea, dysfunctional uterine bleeding, and endometriosis.[17][18] In a normal menstrual cycle, declining levels of progesterone triggers menstruation. Norethisterone acetate and medroxyprogesterone acetate may be used to artificially induce progestogen-associated breakthrough bleeding.[28]

Progestogens are also used to treat benign breast disorders.[29][30] They are associated not only with a reduction in breast pain, but also a decrease in breast cell proliferation, a decrease in breast gland size, and a disappearance of breast nodularity.[29][30][31] Progestogens that have been used for such purposes include topical progesterone, dydrogesterone, promegestone, lynestrenol, medroxyprogesterone acetate, dienogest, and medrogestone.[29][30][32][31]

Gynecological cancers

Progestins were first found to be effective at high dosages in the treatment of endometrial hyperplasia and endometrial cancer in 1959.[33][34][35] Subsequently, high-dosage gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrol acetate were approved for the treatment of endometrial cancer.[36][37][38]

Progestins, such as megestrol acetate and medroxyprogesterone acetate, are effective at high dosages in the treatment of advanced postmenopausal breast cancer.[39][40] They have been extensively evaluated as a second-line therapy for this indication.[39] However, they produce various side effects, such as dyspnea, weight gain, vaginal bleeding, nausea, fluid retention, hypertension, thrombophlebitis, and thromboembolic complications.[39][40] In addition, megestrol acetate has been found to be significantly inferior to aromatase inhibitors in the treatment of breast cancer, and in relation to this, progestins have been moved down in the sequential therapy of the disease.[39] Megestrol acetate is the only Food and Drug Administration-approved progestin for breast cancer.[39] The mechanism of action of progestins in the treatment of breast cancer is unknown, but may be related to their functional antiestrogenic and/or antigonadotropic effects.[39]

Fertility and pregnancy

Progestogens are used in fertility medicine for women. For example, progesterone (or sometimes dydrogesterone or hydroxyprogesterone caproate) is used for luteal support in in-vitro fertilization protocols.[41]

Certain progestins are used to support pregnancy, including hydroxyprogesterone caproate, dydrogesterone, and allylestrenol. They are used questionably for treatment of recurrent pregnancy loss and for prevention of preterm birth in pregnant women with a history of at least one spontaneous preterm birth.[41]

Sex-hormone suppression

Certain progestins are used at high dosages as antigonadotropins to suppress sex hormone production and levels as a form of medical castration for a variety of androgen and estrogen-dependent conditions. Examples of indications include treating prostate cancer, benign prostatic hyperplasia, blocking precocious puberty and puberty in transgender youth, lowering sex hormone levels in transgender people and reducing libido in men with sexual deviance such as in sex offenders, paraphilias, and hypersexuality. Progestins that have been used for such purposes include allylestrenol, chlormadinone acetate,[42] cyproterone acetate, gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone acetate,[43] megestrol acetate, and oxendolone.[44] The progestins that have been used to treat prostate cancer include chlormadinone acetate, cyproterone acetate, medroxyprogesterone acetate, and megestrol acetate.[45][46] However, only chlormadinone acetate and cyproterone acetate have been approved or commonly used for the treatment of prostate cancer.[46]

Some progestins are also antiandrogens, for instance cyproterone acetate, and can be used to treat androgen-dependent conditions like acne and hirsutism in women.

Appetite stimulation

Certain progestins can be used at very high dosages to increase appetite in conditions like cachexia, anorexia, and wasting syndromes. In general, they are used in combination with certain other steroid medications such as dexamethasone. Their effects take several weeks to become apparent, but are relatively long-lived when compared to those of corticosteroids. Furthermore, they are recognized as being the only drugs to increase lean body mass. Megestrol acetate is the lead drug of this class for the management of cachexia, and medroxyprogesterone acetate is also used.[47][48] The mechanism of action of the appetite-related effects of these two drugs is unknown and may not be related to their progestogenic activity.

Available forms

Progestins are available in the form of oral tablets, solutions and suspensions for intramuscular or subcutaneous injection, and a number of other forms (e.g., transdermal patches, vaginal rings, intrauterine devices, subcutaneous implants).

Template:Progestogens marketed for clinical or veterinary use

Contraindications

Contraindications of progestins may include breast cancer and a history of venous thromboembolism among others.[citation needed]

Side effects

Progestogens have relatively few side effects at typical dosages.[49] Side effects of progestins may include tiredness, dysphoria, depression, mood changes, menstrual irregularities, hypomenorrhea, edema, vaginal dryness, vaginal atrophy, headaches, nausea, breast tenderness, decreased libido.[1][2][49] Progestins with androgenic activity, namely 19-nortestosterone derivatives, can also cause acne, hirsutism, seborrhea, voice deepening, changes in liver protein production (e.g., decreased HDL cholesterol, sex hormone-binding globulin), increased appetite, and weight gain, among others.[1][49] Other side effects of progestins include an increased risk of breast cancer, cardiovascular disease, and blood clots, among others.[2] Some of the side effects of progestins are due not to their progestogenic activity but rather due to off-target activities (e.g., androgenic activity, glucocorticoid activity).[1][50] At high dosages, due to their antigonadotropic effects, progestins can cause low sex hormone levels and associated side effects like diminished secondary sexual characteristics, sexual dysfunction (e.g., reduced sex drive and erectile dysfunction), reversible infertility, reduced bone mineral density, and an increased risk of bone fractures, both in men and in premenopausal women.[3]

A 2018 systematic review found no association between progestogen-only contraception and depression in women. However, the systematic review did not use Randomized Placebo-Controlled double blind trials for its review.[51] This is in contrast to other research which found a relationship between hormonal contraceptive use and subsequent prescription antidepressant use.[52]

Overdose

Progestins are relatively safe in acute overdose.[citation needed]

Interactions

Inhibitors and inducers of cytochrome P450 enzymes and other enzymes such as 5α-reductase may interact with progestins.[citation needed]

Pharmacology

Pharmacodynamics

Progestins act by binding to and activating the progesterone receptors (PRs), including the PR-A, PR-B, and PR-C.[1][53][54] Major tissues affected by progestogens include the uterus, cervix, vagina, breasts, and brain.[1] By activating PRs in the hypothalamus and pituitary gland, progestins suppress the secretion of gonadotropins and thereby function as antigonadotropins at sufficiently high dosages.[1] Interaction of progestins with membrane progesterone receptors is less clear.[55][56] Progestins mediate their contraceptive effects in women both by inhibiting ovulation (via their antigonadotropic effects) and by thickening cervical mucus, thereby preventing the possibility of fertilization of the ovum by sperm.[4][5] Progestins have functional antiestrogenic effects in various tissues like the endometrium via activation of the PR, and this underlies their use in menopausal hormone therapy (to prevent unopposed estrogen-induced endometrial hyperplasia and endometrial cancer).[1]

In addition to their progestogenic activity, many progestins have off-target activities such as androgenic, antiandrogenic, estrogenic, glucocorticoid, or antimineralocorticoid activity.[1][2][50] Such actions can contribute both to their beneficial or desirable effects and to their side effects.[1][2][57]

Pharmacodynamics of progestogens
Progestogen Class Off-target activities Relative binding affinities (%)
ES ANTooltip Androgenic AATooltip Antiandrogenic GCTooltip Glucocorticoid AMTooltip Antimineralocorticoid PRTooltip Progesterone receptor ARTooltip Androgen receptor ERTooltip Estrogen receptor GRTooltip Glucocorticoid receptor MRTooltip Mineralocorticoid receptor SHBGTooltip Sex hormone-binding globulin CBGTooltip Corticosteroid binding globulin
Allylestrenola Estrane – ± – – – 1 0 0 0 ? 0 ?
Chlormadinone acetate Pregnane – – + + – 67 5 0 8 0 0 0
Cyproterone acetate Pregnane – – ++ + – 90 6 0 6 8 0 0
Demegestone Norpregnane – – – – – 115 1 0 5 1–2 ? ?
Desogestrela Gonane – + – ± – 1 0 0 0 0 0 0
Dienogest Gonane – – + – – 5 10 0 1 0 0 0
Drospirenone Spirolactone – – + – + 35 65 0 6 230 0 0
Dydrogesteronea Pregnane – – – – ± 75 0 ? ? ? ? ?
Ethisterone Androstane – + – – – 18 0 0 0 0 ? ?
Etonogestrel Gonane – + – ± – 150 20 0 14 0 15 0
Etynodiola,b Estrane + + – – – 1 0 11–18 0 ? ? ?
Etynodiol diacetatea Estrane + + – – – 1 0 0 0 0 ? ?
Gestodene Gonane – + – + + 90–432 85 0 27–38 97–290 40 0
Gestonorone caproate Pregnane – – – – – ? ? ? ? ? ? ?
Hydroxyprogesterone caproate Pregnane – – – – ± ? ? ? ? ? ? ?
Levonorgestrel Gonane – + – – – 150–162 45 0 1–8 17–75 50 0
Lynestrenola Estrane + + – – – 1 1 3 0 0 ? ?
Medrogestone Pregnane – – ± – – ? ? ? ? ? ? ?
Medroxyprogesterone acetate Pregnane – ± – + – 115–149 5 0 29–58 3–160 0 0
Megestrol acetate Pregnane – ± + + – 65 5 0 30 0 0 0
Nomegestrol acetate Norpregnane – – + – – 125 42 0 6 0 0 0
Norelgestromin Gonane – ± – – – 10 0 ? ? ? 0 ?
Norethisterone Estrane + + – – – 67–75 15 0 0–1 0–3 16 0
Norethisterone acetatea Estrane + + – – – 20 5 1 0 0 ? ?
Norethisterone enanthatea Estrane + + – – – ? ? ? ? ? ? ?
Noretynodrela Estrane + ± – – – 6 0 2 0 0 0 0
Norgestimatea Gonane – + – – – 15 0 0 1 0 0 0
Progesterone Pregnane – – ± + + 50 0 0 10 100 0 36
Promegestonea Norpregnane – – – + – 100 0 0 5 53 0 0
Segesterone acetate Norpregnane – – – – – 136 0 0 38 ? 0 ?
Tibolonea Estrane + ++ – – – 6 6 1 ? ? ?
Δ4-Tiboloneb Estrane – ++ – – – 90 35 1 0 2 1 0
Trimegestone Norpregnane – – ± – ± 294–330 1 0 9–13 42–120 ? ?
Footnotes: a = Prodrug. b = Metabolite (non-marketed). Class: Pregnane = Progesterone derivative. Norpregnane = 19-Norprogesterone derivative. Androstane = Testosterone derivative. Estrane = 19-Nortestosterone derivative. Gonane = 13β-Ethylgonane = 18-Methyl-19-nortestosterone derivative. Spirolactone = Spirolactone derivative. Magnitude: ++ = High. + = Moderate. ± = Low. – = None. Activity: ES = Estrogenic. AN = Androgenic. AA = Antiandrogenic. GC = Glucocorticoid. AM = Antimineralocorticoid. Binding: PRTooltip Progesterone receptor: Promegestone = 100%. ARTooltip Androgen receptor: Metribolone = 100%. ERTooltip estrogen receptor: Estradiol = 100%. GRTooltip Glucocorticoid receptor: Dexamethasone = 100%. MRTooltip Mineralocorticoid receptor: Aldosterone = 100%. SHBGTooltip Sex hormone-binding globulin: DHT = 100%. CBGTooltip Corticosteroid-binding globulin: Cortisol = 100%. Sources: See template.

Template:Pharmacodynamics of progestin metabolites

Oral potencies of progestogens[data 1]
Compound Doses for specific uses (mg/day)[a]
OID TFD MDT BCPD ECD
Cycle Daily
Allylestrenol 25 150–300 - 30 – -
Bromoketoprogesterone[b] - - 100–160 - – -
Chlormadinone acetate 1.5–4.0 20–30 3–10 1.0–4.0 2.0 5–10
Cyproterone acetate 1.0 20–30 1.0–3.0 1.0–4.0 2.0 1.0
Desogestrel 0.06 0.4–2.5 0.15 0.25 0.15 0.15
Dienogest 1.0 6.0–6.3 - - 2.0–3.0 2.0
Drospirenone 2.0 40–80 - - 3.0 2.0
Dydrogesterone >30 140–200 10–20 20 – 10
Ethisterone - 200–700 50–250 - – -
Etynodiol diacetate 2.0 10–15 - 1.0 1.0–20 -
Gestodene 0.03 2.0–3.0 - - 0.06–0.075 0.20
Hydroxyprogest. acetate - - 70–125 - 100 -
Hydroxyprogest. caproate - 700–1400 70 - – -
Levonorgestrel 0.05 2.5–6.0 0.15–0.25 0.5 0.1–0.15 0.075
Lynestrenol 2.0 35–150 5.0 10 - -
Medrogestone 10 50–100 10 15 – 10
Medroxyprogest. acetate 10 40–120 2.5–10 20–30 5–10 5.0
Megestrol acetate >5[c] 30–70 - 5–10 1.0–5.0 5.0
Nomegestrol acetate 1.25–5.0 100 5.0 - 2.5 3.75–5.0
Norethandrolone[b] - - 10 - – -
Norethisterone 0.4–0.5 100–150 5–10 10–15 0.5 0.7–1.0
Norethisterone acetate 0.5 30–60 2.5–5.0 7.5 0.6 1.0
Norethist. acetate (micron.) - 12–14 - - – -
Noretynodrel 4.0 150–200 - 14 2.5–10 -
Norgestimate 0.2 2.0–10 - - 0.25 0.09
Norgestrel 0.1 12 - 0.5–2.0 - -
Normethandrone - 150 10 - – -
Progesterone (non-micron.) >300[d] - - - - -
Progesterone (micronized) - 4200 200–300 1000 – 200
Promegestone 0.5 10 0.5 - – 0.5
Tibolone 2.5 - - - – -
Trengestone - 50–70 - - – -
Trimegestone 0.5 - 0.25–0.5 - – 0.0625–0.5
Notes and sources
  1. ^ [58][6][59][49][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75]
  1. ^ Dosages are expressed in mg/day unless otherwise noted
  2. ^ a b Never marketed as a progestogen.
  3. ^ The exact OID of MGA is unknown, but it is known to be greater than 5 mg/day.[76][77][78]
  4. ^ Ovulation inhibition rate with 300 to 1,000 mg/day oral non-micronized P4 was incomplete.[79][70][80][81][82][83]

Antigonadotropic effects

Progestogens, similarly to the androgens and estrogens through their own respective receptors, inhibit the secretion of the gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) via activation of the PR in the pituitary gland. This effect is a form of negative feedback on the hypothalamic–pituitary–gonadal axis (HPG axis) and takes advantage of the mechanism that the body uses to prevent sex hormone levels from becoming too high.[84][42][85] Accordingly, progestogens, both endogenous and exogenous (i.e., progestins), have antigonadotropic effects,[44] and progestins in sufficiently high amounts can markedly suppress the body's normal production of progestogens, androgens, and estrogens as well as inhibit fertility (ovulation in women and spermatogenesis in men).[85]

Progestins have been found to maximally suppress circulating testosterone levels in men by up to 70 to 80% at sufficiently high dosages.[86][87] This is notably less than that achieved by GnRH analogues, which can effectively abolish gonadal production of testosterone and suppress circulating testosterone levels by as much as 95%.[88] It is also less than that achieved by high-dose estrogen therapy, which can suppress testosterone levels into the castrate range similarly to GnRH analogues.[89]

The retroprogesterone derivatives dydrogesterone and trengestone are atypical progestogens and unlike all other clinically used progestogens do not have antigonadotropic effects nor inhibit ovulation even at very high dosages.[1][90] In fact, trengestone may have progonadotropic effects, and is actually able to induce ovulation, with about a 50% success rate on average.[90] These progestins also show other atypical properties relative to other progestogens, such as a lack of a hyperthermic effect.[1][90]

Androgenic activity

See also: Progestin-induced virilization

Some progestins have androgenic activity and can produce androgenic side effects such as increased sebum production (oilier skin), acne, and hirsutism (excessive facial/body hair growth), as well as changes in liver protein production.[91][92][93] Only certain progestins are androgenic however, these being the testosterone derivatives and, to a lesser extent, the 17α-hydroxyprogesterone derivatives medroxyprogesterone acetate and megestrol acetate.[94][92][58] No other progestins have such activity (though some, conversely, possess antiandrogenic activity).[92][58] Moreover, the androgenic activity of progestins within the testosterone derivatives also varies, and while some may have high or moderate androgenic activity, others have only low or no such activity.[21][95]

The androgenic activity of androgenic progestins is mediated by two mechanisms: 1) direct binding to and activation of the androgen receptor; and 2) displacement of testosterone from sex hormone-binding globulin (SHBG), thereby increasing free (and thus bioactive) testosterone levels.[96] The androgenic activity of many androgenic progestins is offset by combination with ethinylestradiol, which robustly increases SHBG levels, and most oral contraceptives in fact markedly reduce free testosterone levels and can treat or improve acne and hirsutism.[96] An exception is progestin-only contraceptives, which do not also contain an estrogen.[96]

The androgenic activity of testosterone-derivative progestins and other progestins that have androgenic activity can be roughly ranked as follows:

It should be noted however that the clinical androgenic and anabolic activity of the androgenic progestins listed above is still far lower than that of conventional androgens and anabolic steroids like testosterone and nandrolone esters. As such, they are only generally associated with such effects in women and often only at high dosages. In men, due to their concomitant progestogenic activity and by extension antigonadotropic effects, these progestins can have potent functional antiandrogenic effects via suppression of testosterone production and levels.

Antiandrogenic activity

Some progestins have antiandrogenic activity in addition to their progestogenic activity.[114] These progestins, with varying degrees of potency as antiandrogens, include chlormadinone acetate, cyproterone acetate, dienogest, drospirenone, medrogestone, megestrol acetate, nomegestrol acetate, osaterone acetate (veterinary), and oxendolone.[114][113][115][116] The relative antiandrogenic activity in animals of some of these progestins has been ranked as follows: cyproterone acetate (100%) > nomegestrol acetate (90%) > dienogest (30–40%) ≥ chlormadinone acetate (30%) = drospirenone (30%).[1][117] Antiandrogenic activity in certain progestins may help to improve symptoms of acne, seborrhea, hirsutism, and other androgen-dependent conditions in women.[1][114]

Estrogenic activity

A few progestins have weak estrogenic activity.[1] These include the 19-nortestosterone derivatives norethisterone, noretynodrel, and tibolone, as well as the norethisterone prodrugs[118] norethisterone acetate, norethisterone enanthate, lynestrenol, and etynodiol diacetate.[1] The estrogenic activity of norethisterone and its prodrugs are due to metabolism into ethinylestradiol.[1] High dosages of norethisterone and noretynodrel have been associated with estrogenic side effects such as breast enlargement in women and gynecomastia in men, but also with alleviation of menopausal symptoms in postmenopausal women.[119] In contrast, non-estrogenic progestins were not found to be associated with such effects.[119]

Glucocorticoid activity

Some progestins, mainly certain 17α-hydroxyprogesterone derivatives, have weak glucocorticoid activity.[120] This can result, at sufficiently high dosages, in side effects such as symptoms of Cushing's syndrome, steroid diabetes, adrenal suppression and insufficiency, and neuropsychiatric symptoms like depression, anxiety, irritability, and cognitive impairment.[120][121][122] Progestins with the potential for clinically relevant glucocorticoid effects include the 17α-hydroxyprogesterone derivatives chlormadinone acetate, cyproterone acetate, medroxyprogesterone acetate, megestrol acetate, promegestone, and segesterone acetate and the testosterone derivatives desogestrel, etonogestrel, and gestodene.[1][121][123][124] Conversely, hydroxyprogesterone caproate possesses no such activity, while progesterone itself has very weak glucocorticoid activity.[125][1]

Glucocorticoid activity of selected steroids in vitro
Steroid Class TRTooltip Thrombin receptor (↑)a GRTooltip glucocorticoid receptor (%)b
Dexamethasone Corticosteroid ++ 100
Ethinylestradiol Estrogen – 0
Etonogestrel Progestin + 14
Gestodene Progestin + 27
Levonorgestrel Progestin – 1
Medroxyprogesterone acetate Progestin + 29
Norethisterone Progestin – 0
Norgestimate Progestin – 1
Progesterone Progestogen + 10
Footnotes: a = Thrombin receptor (TR) upregulation (↑) in vascular smooth muscle cells (VSMCs). b = RBATooltip Relative binding affinity (%) for the glucocorticoid receptor (GR). Strength: – = No effect. + = Pronounced effect. ++ = Strong effect. Sources: [126]

Antimineralocorticoid activity

Certain progestins, including drospirenone and gestodene and to a lesser extent dydrogesterone and trimegestone, have varying degrees of antimineralocorticoid activity.[1][57] Progesterone itself has potent antimineralocorticoid activity.[1] No clinically used progestins are known to have mineralocorticoid activity.[1] Progestins with potent antimineralocorticoid activity like drospirenone may have properties more similar to those of natural progesterone, such as counteraction of cyclical estrogen-induced sodium and fluid retention, edema, and associated weight gain; lowered blood pressure; and possibly improved cardiovascular health.[127][128][129][130]

Neurosteroid activity

Progesterone has neurosteroid activity via metabolism into allopregnanolone and pregnanolone, potent positive allosteric modulators of the GABAA receptor.[1] As a result, it has associated effects such as sedation, somnolence, and cognitive impairment.[1] No progestin is known to have similar such neurosteroid activity or effects.[1] However, promegestone has been found to act as a non-competitive antagonist of the nicotinic acetylcholine receptor similarly to progesterone.[131]

Pharmacokinetics

Pharmacokinetics of progestogens
Progestogen Class Dosea Bioavailability Half-lifeTooltip Elimination half-life
Allylestrenol Estrane NA ? Prodrug
Chlormadinone acetate Pregnane 2 mg ~100% 80 hours
Cyproterone acetate Pregnane 2 mg ~100% 54–79 hours
Desogestrel Gonane 0.15 mg 63% Prodrug
Dienogest Gonane 4 mg 96% 11–12 hours
Drospirenone Spirolactone 3 mg 66% 31–33 hours
Dydrogesterone Pregnane 10 mg 28% 14–17 hours
Etynodiol diacetate Estrane NA ? Prodrug
Gestodene Gonane 0.075 mg 88–99% 12–14 hours
Hydroxyprogesterone caproate Pregnane ND – 8 daysb
Levonorgestrel Gonane 0.15–0.25 mg 90% 10–13 hours
Lynestrenol Estrane NA ? Prodrug
Medrogestone Pregnane 5 mg ~100% 35 hours
Medroxyprogesterone acetate Pregnane 10 mg ~100% 24 hours
Megestrol acetate Pregnane 160 mg ~100% 22 hours
Nomegestrol acetate Pregnane 2.5 mg 60% 50 hours
Norethisterone Estrane 1 mg 64% 8 hours
Norethisterone acetate Estrane NA ? Prodrug
Noretynodrel Estrane NA ? Prodrug
Norgestimate Gonane NA ? Prodrug
Progesterone (micronized) Pregnane 100–200 mg <2.4% 5 hours
Promegestone Pregnane NA ? Prodrug
Tibolone Estrane NA ? Prodrug
Trimegestone Pregnane 0.5 mg ~100% 15 hours
Notes: All by oral administration, unless otherwise noted. Footnotes: a = For the listed pharmacokinetic values. b = By intramuscular injection. Sources: See template.

Chemistry

See also: List of progestogens, Progestogen ester, and List of progestogen esters

All currently available progestins are steroids.[1] They include the pregnanes (e.g., dydrogesterone, medroxyprogesterone acetate) and norpregnanes (e.g., nomegestrol acetate), which are derivatives of progesterone, and the androstanes (e.g., danazol, ethisterone) and estranes (e.g., norethisterone, levonorgestrel), which are testosterone derivatives.[1] These groups can be further divided into various subgroups.[1]

History

The recognition of progesterone's ability to suppress ovulation during pregnancy spawned a search for a similar hormone that could bypass the problems associated with administering progesterone (e.g. low bioavailability when administered orally and local irritation and pain when continually administered parenterally) and, at the same time, serve the purpose of controlling ovulation. The many synthetic hormones that resulted are known as progestins.

The first orally active progestin, ethisterone (pregneninolone, 17α-ethynyltestosterone), the 17α-ethynyl analog of testosterone, was synthesized in 1938 from dehydroandrosterone by ethynylation, either before or after oxidation of the 3-OH group, followed by rearrangement of the 5,6 double bond to the 4,5 position. The synthesis was designed by chemists Hans Herloff Inhoffen, Willy Logemann, Walter Hohlweg and Arthur Serini at Schering AG in Berlin and was marketed in Germany in 1939 as Proluton C and by Schering in the U.S. in 1945 as Pranone.[132][133][134][135][136]

A more potent orally active progestin, norethisterone (norethindrone, 19-nor-17α-ethynyltestosterone), the 19-nor analog of ethisterone, synthesized in 1951 by Carl Djerassi, Luis Miramontes, and George Rosenkranz at Syntex in Mexico City, was marketed by Parke-Davis in the U.S. in 1957 as Norlutin, and was used as the progestin in some of the first oral contraceptives (Ortho-Novum, Norinyl, etc.) in the early 1960s.[133][133][134][135][136][137]

Noretynodrel, an isomer of norethisterone, was synthesized in 1952 by Frank B. Colton at Searle in Skokie, Illinois and used as the progestin in Enovid, marketed in the U.S. in 1957 and approved as the first oral contraceptive in 1960.[133][134][135][136][138]

Introduction of first-generation oral contraceptives
Progestin Estrogen Brand name Manufacturer U.S. Approval U.K. Approval
Noretynodrel Mestranol Enovid Searle 1960 1963
Norethisterone Mestranol Ortho-Novum, Norinyl Syntex/Ortho 1963 1966
Norethisterone Ethinylestradiol Norlestrin Syntex/Parke-Davis 1964 1962
Lynestrenol Mestranol Lyndiol Organon N/A 1963
Megestrol acetate Ethinylestradiol Volidan, Nuvacon British Drug Houses N/A 1963
Norethisterone acetate Ethinylestradiol Norlestrin Parke-Davis 1964 N/D
Quingestanol acetate Ethinylestradiol Riglovis Vister[139] N/A N/A
Quingestanol acetate Quinestrol Unovis Warner Chilcott[139] N/A N/A
Medroxyprogesterone acetate Ethinylestradiol Provest Upjohn 1964 N/A
Chlormadinone acetate Mestranol C-Quens Merck 1965 1965
Dimethisterone Ethinylestradiol Oracon British Drug Houses 1965 N/A
Etynodiol diacetate Mestranol Ovulen Searle 1966 1965
Etynodiol diacetate Ethinylestradiol Demulen Searle 1970 1968
Norgestrienone Ethinylestradiol Planor, Miniplanor Roussel Uclaf[139] N/A N/A
Norgestrel Ethinylestradiol Ovral Wyeth 1968 1972
Anagestone acetate Mestranol Neo-Novum Ortho[140] N/A N/A
Lynestrenol Ethinylestradiol Lyndiol[141] Organon N/A 1969
Sources:[107][142][143][144]

Society and culture

Generations

Progestins used in birth control are sometimes grouped, somewhat arbitrarily and fairly inconsistently, into generations. One definition of these generations is as follows:[14]

Alternatively, estranes such as noretynodrel and norethisterone are classified as first-generation while gonanes such as norgestrel and levonorgestrel are classified as second-generation, with less androgenic gonanes such as desogestrel, norgestimate, and gestodene classified as third-generation and newer progestins like drospirenone classified as fourth-generation.[15] Yet another classification system considers there to be only first- and second-generation progestins.[citation needed]

Availability

See also: List of progestogens available in the United States

Progestins are available widely throughout the world in many different forms. They are present in all birth control pills.

Research

A variety of progestins have been studied for use as potential male hormonal contraceptives in combination with androgens in men.[24] These include the pregnanes medroxyprogesterone acetate, megestrol acetate, and cyproterone acetate, the norpregnane segesterone acetate, and the estranes norethisterone acetate, norethisterone enanthate, levonorgestrel, levonorgestrel butanoate, desogestrel, and etonogestrel.[24][145][146][147] The androgens that have been used in combination with these progestins include testosterone, testosterone esters, androstanolone (dihydrotestosterone), and nandrolone esters.[24] Dual androgens and progestins such as trestolone and dimethandrolone undecanoate have also been developed and studied as male contraceptives.[148][149]

See also

References

  1. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  2. ^ a b c d e f Wiegratz I, Kuhl H (2004). "Progestogen therapies: differences in clinical effects?". Trends Endocrinol. Metab. 15 (6): 277–85. doi:10.1016/j.tem.2004.06.006. PMID 15358281.
  3. ^ a b Thibaut F, De La Barra F, Gordon H, Cosyns P, Bradford JM (2010). "The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias". World J. Biol. Psychiatry. 11 (4): 604–55. doi:10.3109/15622971003671628. PMID 20459370.
  4. ^ a b Glasier, Anna (March 20, 2015). "Chapter 134. Contraception". In Jameson, J. Larry; De Groot, Leslie J.; de Krester, David; Giudice, Linda C.; Grossman, Ashley; Melmed, Shlomo; Potts, John T., Jr.; Weir, Gordon C. (eds.). Endocrinology: Adult and Pediatric (7th ed.). Philadelphia: Saunders Elsevier. p. 2306. ISBN 978-0-323-18907-1.{{cite book}}: CS1 maint: multiple names: editors list (link)
  5. ^ a b Pattman, Richard; Sankar, K. Nathan; Elewad, Babiker; Handy, Pauline; Price, David Ashley, eds. (November 19, 2010). "Chapter 33. Contraception including contraception in HIV infection and infection reduction". Oxford Handbook of Genitourinary Medicine, HIV, and Sexual Health (2nd ed.). Oxford: Oxford University Press. p. 360. ISBN 978-0-19-957166-6. Ovulation may be suppressed in 15–40% of cycles by POPs containg levonorgestrel, norethisterone, or etynodiol diacetate, but in 97–99% by those containing desogestrel. {{cite book}}: External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
  6. ^ a b c Kuhl H (2011). "Pharmacology of Progestogens" (PDF). J Reproduktionsmed Endokrinol. 8 (1): 157–177.
  7. ^ a b Christian Lauritzen; John W. W. Studd (22 June 2005). Current Management of the Menopause. CRC Press. p. 45. ISBN 978-0-203-48612-2. Ethisterone, the first orally effective progestagen, was synthesized by Inhoffen and Hohlweg in 1938. Norethisterone, a progestogen still used worldwide, was synthesized by Djerassi in 1951. But this progestogen was not used immediately and in 1953 Colton discovered norethynodrel, used by Pincus in the first oral contraceptive. Numerous other progestogens were subsequently synthesized, e.g., lynestrenol and ethynodiol diacetate, which were, in fact, prhormones converted in vivo to norethisterone. All these progestogens were also able to induce androgenic effects when high doses were used. More potent progestogens were synthesized in the 1960s, e.g. norgestrel, norgestrienone. These progestogens were also more androgenic.
  8. ^ Klaus Roth (2014). Chemische Leckerbissen. John Wiley & Sons. p. 69. ISBN 978-3-527-33739-2. Im Prinzip hatten Hohlweg und Inhoffen die Lösung schon 1938 in der Hand, denn ihr Ethinyltestosteron (11) war eine oral wirksame gestagene Verbindung und Schering hatte daraus bereits 1939 ein Medikament (Proluton C®) entwickelt.
  9. ^ a b http://www.micromedexsolutions.com
  10. ^ a b Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. ISBN 978-0-85369-840-1.
  11. ^ a b https://www.drugs.com/drug-class/progestins.html
  12. ^ a b Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. ISBN 978-3-88763-075-1.
  13. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. ISBN 978-1-4757-2085-3.
  14. ^ a b John David Gordon; Jan Rydfors; Maurice Druzin; Yasser El-Sayed; Yona Tadir (2007). Obstetrics, Gynecology & Infertility: Handbook for Clinicians. Scrub Hill Press, Inc. pp. 229–. ISBN 978-0-9645467-7-6.
  15. ^ a b Ronald S. Gibbs (2008). Danforth's Obstetrics and Gynecology. Lippincott Williams & Wilkins. pp. 568–. ISBN 978-0-7817-6937-2.
  16. ^ J. Larry Jameson; Leslie J. De Groot (25 February 2015). Endocrinology: Adult and Pediatric E-Book. Elsevier Health Sciences. pp. 2304–. ISBN 978-0-323-32195-2.
  17. ^ a b Michelle A. Clark; Richard A. Harvey; Richard Finkel; Jose A. Rey; Karen Whalen (15 December 2011). Pharmacology. Lippincott Williams & Wilkins. p. 322. ISBN 978-1-4511-1314-3.
  18. ^ a b Bhattacharya (1 January 2003). Pharmacology, 2/e. Elsevier India. p. 378. ISBN 978-81-8147-009-6.
  19. ^ Rick D. Kellerman; Edward T. Bope (10 November 2017). Conn's Current Therapy 2018 E-Book. Elsevier Health Sciences. pp. 1124–. ISBN 978-0-323-52961-7.
  20. ^ Helen Varney; Jan M. Kriebs; Carolyn L. Gegor (2004). Varney's Midwifery. Jones & Bartlett Learning. pp. 513–. ISBN 978-0-7637-1856-5.
  21. ^ a b c d David E. Golan (2008). Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Lippincott Williams & Wilkins. pp. 520–521. ISBN 978-0-7817-8355-2.
  22. ^ Pamela S. Miles; William F. Rayburn; J.Christopher Carey (6 December 2012). Obstetrics and Gynecology. Springer Science & Business Media. pp. 109–. ISBN 978-1-4684-0220-9.
  23. ^ a b Erkkola R, Landgren BM (March 2005). "Role of progestins in contraception". Acta Obstet Gynecol Scand. 84 (3): 207–16. doi:10.1111/j.0001-6349.2005.00759.x. PMID 15715527.
  24. ^ a b c d Nieschlag E (2010). "Clinical trials in male hormonal contraception" (PDF). Contraception. 82 (5): 457–70. doi:10.1016/j.contraception.2010.03.020. PMID 20933120.
  25. ^ Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR (2007). "Estrogenic side effects of androgen deprivation therapy". Rev Urol. 9 (4): 163–80. PMC 2213888. PMID 18231613.
  26. ^ Frisk J (2010). "Managing hot flushes in men after prostate cancer--a systematic review". Maturitas. 65 (1): 15–22. doi:10.1016/j.maturitas.2009.10.017. PMID 19962840.
  27. ^ Koike H, Morikawa Y, Matsui H, Shibata Y, Ito K, Suzuki K (2013). "Chlormadinone acetate is effective for hot flush during androgen deprivation therapy". Prostate Int. 1 (3): 113–6. doi:10.12954/PI.12010. PMC 3814123. PMID 24223412.
  28. ^ Hickey M, Fraser IS (August 2000). "A functional model for progestogen-induced breakthrough bleeding". Hum. Reprod. 15 Suppl 3: 1–6. doi:10.1093/humrep/15.suppl_3.1. PMID 11041215.
  29. ^ a b c Schindler AE (February 2011). "Dydrogesterone and other progestins in benign breast disease: an overview". Arch. Gynecol. Obstet. 283 (2): 369–71. doi:10.1007/s00404-010-1456-7. PMID 20383772.
  30. ^ a b c Winkler UH, Schindler AE, Brinkmann US, Ebert C, Oberhoff C (December 2001). "Cyclic progestin therapy for the management of mastopathy and mastodynia". Gynecol. Endocrinol. 15 Suppl 6: 37–43. PMID 12227885.
  31. ^ a b Ruan X, Mueck AO (2014). "Systemic progesterone therapy--oral, vaginal, injections and even transdermal?". Maturitas. 79 (3): 248–55. doi:10.1016/j.maturitas.2014.07.009. PMID 25113944.
  32. ^ Bińkowska, Małgorzata; Woroń, Jarosław (2015). "Progestogens in menopausal hormone therapy". Menopausal Review. 2: 134–143. doi:10.5114/pm.2015.52154. ISSN 1643-8876.
  33. ^ Kistner RW (1959). "Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium". Cancer. 12: 1106–22. doi:10.1002/1097-0142(195911/12)12:6<1106::aid-cncr2820120607>3.0.co;2-m. PMID 14409476.
  34. ^ Regulatory Mechanisms in Transcriptional Signaling. Academic Press. 25 July 2009. pp. 62–. ISBN 978-0-08-091198-4.
  35. ^ Loren K. Mell, MD (20 December 2011). Gynecologic Cancer. Demos Medical Publishing. pp. 393–. ISBN 978-1-61705-095-4.
  36. ^ Robert G. McKinnell (13 March 1998). The Biological Basis of Cancer. Cambridge University Press. pp. 262–. ISBN 978-0-521-59695-4.
  37. ^ Jacqueline Burchum; Laura Rosenthal (2 December 2014). Lehne's Pharmacology for Nursing Care - E-Book. Elsevier Health Sciences. pp. 740–. ISBN 978-0-323-34026-7.
  38. ^ H. John Smith; Hywel Williams (10 October 2005). Smith and Williams' Introduction to the Principles of Drug Design and Action, Fourth Edition. CRC Press. pp. 493–. ISBN 978-0-203-30415-0.
  39. ^ a b c d e f David J. Winchester (2006). Breast Cancer. PMPH-USA. pp. 333–. ISBN 978-1-55009-272-1.
  40. ^ a b Gadducci A, Genazzani AR (December 1999). "Endocrine therapy for gynecological cancer". Gynecol. Endocrinol. 13 (6): 441–56. doi:10.3109/09513599909167590. PMID 10685337.
  41. ^ a b Loose, Davis S.; Stancel, George M. (2006). "Estrogens and Progestins". In Brunton, Laurence L.; Lazo, John S.; Parker, Keith L. (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th ed.). New York: McGraw-Hill. pp. 1541–71. ISBN 0-07-142280-3.
  42. ^ a b Chassard D, Schatz B (2005). "[The antigonadrotropic activity of chlormadinone acetate in reproductive women]". Gynécologie, Obstétrique & Fertilité (in French). 33 (1–2): 29–34. doi:10.1016/j.gyobfe.2004.12.002. PMID 15752663.
  43. ^ Andrea R. Genazzani (15 January 1993). Frontiers in Gynecologic and Obstetric Investigation. Taylor & Francis. p. 320. ISBN 978-1-85070-486-7. Retrieved 29 May 2012.
  44. ^ a b Neumann F (1978). "The physiological action of progesterone and the pharmacological effects of progestogens--a short review". Postgraduate Medical Journal. 54 Suppl 2: 11–24. PMID 368741.
  45. ^ Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS (January 2006). "Secondary hormonal therapy for advanced prostate cancer". J. Urol. 175 (1): 27–34. doi:10.1016/S0022-5347(05)00034-0. PMID 16406864.
  46. ^ a b Fourcade RO, Chatelain C (July 1998). "Androgen deprivation for prostatic carcinoma: a rationale for choosing components". Int. J. Urol. 5 (4): 303–11. doi:10.1111/j.1442-2042.1998.tb00356.x. PMID 9712436.
  47. ^ Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D (March 2001). "High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials". Ann. Oncol. 12 (3): 289–300. doi:10.1023/a:1011156811739. PMID 11332139.
  48. ^ Lelli G, Montanari M, Gilli G, Scapoli D, Antonietti C, Scapoli D (June 2003). "Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal". J Chemother. 15 (3): 220–5. doi:10.1179/joc.2003.15.3.220. PMID 12868546.
  49. ^ a b c d Lauritzen C (September 1990). "Clinical use of oestrogens and progestogens". Maturitas. 12 (3): 199–214. doi:10.1016/0378-5122(90)90004-P. PMID 2215269. Cite error: The named reference "pmid2215269" was defined multiple times with different content (see the help page).
  50. ^ a b Africander D, Verhoog N, Hapgood JP (June 2011). "Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception". Steroids. 76 (7): 636–52. doi:10.1016/j.steroids.2011.03.001. PMID 21414337.
  51. ^ Worly, Brett L.; Gur, Tamar L.; Schaffir, Jonathan (2018). "The relationship between progestin hormonal contraception and depression: a systematic review". Contraception. doi:10.1016/j.contraception.2018.01.010. ISSN 0010-7824.
  52. ^ Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø (November 2016). "Association of Hormonal Contraception With Depression". JAMA Psychiatry. 73 (11): 1154–1162. doi:10.1001/jamapsychiatry.2016.2387. PMID 27680324.
  53. ^ Jacobsen BM, Horwitz KB (2012). "Progesterone receptors, their isoforms and progesterone regulated transcription". Mol. Cell. Endocrinol. 357 (1–2): 18–29. doi:10.1016/j.mce.2011.09.016. PMC 3272316. PMID 21952082.
  54. ^ Scarpin KM, Graham JD, Mote PA, Clarke CL (2009). "Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression". Nucl Recept Signal. 7: e009. doi:10.1621/nrs.07009. PMC 2807635. PMID 20087430.
  55. ^ Thomas P, Pang Y (2012). "Membrane progesterone receptors: evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells". Neuroendocrinology. 96 (2): 162–71. doi:10.1159/000339822. PMC 3489003. PMID 22687885.
  56. ^ Petersen SL, Intlekofer KA, Moura-Conlon PJ, Brewer DN, Del Pino Sans J, Lopez JA (2013). "Novel progesterone receptors: neural localization and possible functions". Frontiers in Neuroscience. 7: 164. doi:10.3389/fnins.2013.00164. PMC 3776953. PMID 24065878.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  57. ^ a b Regidor PA, Schindler AE (2017). "Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone". Oncotarget. 8 (47): 83334–83342. doi:10.18632/oncotarget.19833. PMC 5669973. PMID 29137347.
  58. ^ a b c Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (December 2003). "Classification and pharmacology of progestins". Maturitas. 46 Suppl 1: S7–S16. doi:10.1016/j.maturitas.2003.09.014. PMID 14670641. Cite error: The named reference "pmid14670641" was defined multiple times with different content (see the help page).
  59. ^ Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  60. ^ Kuhl H (September 1990). "Pharmacokinetics of oestrogens and progestogens". Maturitas. 12 (3): 171–97. doi:10.1016/0378-5122(90)90003-o. PMID 2170822.
  61. ^ Knörr, Karl; Knörr-Gärtner, Henriette; Beller, Fritz K.; Lauritzen, Christian (8 March 2013). Geburtshilfe und Gynäkologie: Physiologie und Pathologie der Reproduktion. Springer-Verlag. pp. 583–. ISBN 978-3-642-95583-9.
  62. ^ Knörr, Karl; Beller, Fritz K.; Lauritzen, Christian (17 April 2013). Lehrbuch der Gynäkologie. Springer-Verlag. pp. 214–. ISBN 978-3-662-00942-0.
  63. ^ Horský, Jan; Presl, Jiří (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". In J. Horsky; J. Presl (eds.). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 309–332. doi:10.1007/978-94-009-8195-9_11. ISBN 978-94-009-8195-9.
  64. ^ Ferin J (September 1972). "Orally Active Progestational Compounds. Human Studies: Effects on the Utero-Vaginal Tract". In M. Tausk (ed.). Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. Vol. II. Pergamon Press. pp. 245–273. ISBN 978-0080168128. OCLC 278011135.
  65. ^ Freimut A. Leidenberger; Thomas Strowitzki; Olaf Ortmann (29 August 2009). Klinische Endokrinologie für Frauenärzte. Springer-Verlag. pp. 225, 227. ISBN 978-3-540-89760-6.
  66. ^ Neumann F, Düsterberg B (1998). "Entwicklung auf dem Gebiet der Gestagene" [Development in the field of progestogens]. Reproduktionsmedizin. 14 (4): 257–264. doi:10.1007/s004440050042. ISSN 1434-6931.
  67. ^ Hammerstein, J. (1990). "Antiandrogens: Clinical Aspects". Hair and Hair Diseases. pp. 827–886. doi:10.1007/978-3-642-74612-3_35.
  68. ^ Willibald Pschyrembel (1968). Praktische Gynäkologie: für Studierende und Ärzte. Walter de Gruyter. p. 599. ISBN 978-3-11-150424-7.
  69. ^ Ufer, Joachim (1968). "Die therapeutische Anwendung der Gestagene beim Menschen" [Therapeutic Use of Progestagens in Humans]. Die Gestagene [Progestogens]. Springer-Verlag. pp. 1026–1124. doi:10.1007/978-3-642-99941-3_7. ISBN 978-3-642-99941-3. Zur Transformation des Endometriums benotigten sie 200-400 mg [ethisterone] pro Cyclus und postulierten eine etwa sechsfach schwachere Wirkung gegenuber dem Progesteron i.m. appliziert.
  70. ^ a b Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B (December 2011). "Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide". Contraception. 84 (6): 549–57. doi:10.1016/j.contraception.2011.04.009. PMID 22078182. Table 1 Publications on ovulation inhibition doses of progestins: Progestin: Progesterone. Reference: Pincus (1956). Method: Urinary Pdiol. Daily dose (mg): 300.000. Total number of cycles in all subjects: 61. Total number of ovulation in all subjects: 30. % of ovulation in all subjects: 49.
  71. ^ Milan Rastislav Henzl; John A. Edwards (10 November 1999). "Pharmacology of Progestins: 17α-Hydroxyprogesterone Derivatives and Progestins of the First and Second Generation". In Régine Sitruk-Ware; Daniel R. Mishell (eds.). Progestins and Antiprogestins in Clinical Practice. Taylor & Francis. pp. 101–132. ISBN 978-0-8247-8291-7.
  72. ^ Kopera, Hans (1991). "Hormone der Gonaden". Hormonelle Therapie für die Frau. pp. 59–124. doi:10.1007/978-3-642-95670-6_6. ISBN 978-3-642-95670-6. ISSN 0172-777X.
  73. ^ IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). "Annex 2: Composition of Oral and Injectable Estrogen–Progestogen Contraceptives". Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 431–464. ISBN 978-92-832-1291-1.
  74. ^ Lobo, Rogerio A.; Stanczyk, Frank Z. (1994). "New knowledge in the physiology of hormonal contraceptives". American Journal of Obstetrics and Gynecology. 170 (5): 1499–1507. doi:10.1016/S0002-9378(12)91807-4. ISSN 0002-9378.
  75. ^ Henzl, Milan R. (1986). "Contraceptive Hormones and their Clinical Use". In Samuel S. C. Yen; Robert B. Jaffe (eds.). Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. Saunders. pp. 643–682. ISBN 978-0-7216-9630-0.
  76. ^ Ostergaard E (February 1965). "The oral progestational and anti-ovulatory properties of megestrol acetate and its therapeutic use in gynaecological disorders". J Obstet Gynaecol Br Emp. 72 (1): 45–48. doi:10.1111/j.1471-0528.1965.tb01372.x. PMID 12332461. The anti-ovulatory properties of megestrol acetate 5 mg. plus Mestranol 0.1 mg. were demonstrated in thirty-five women by direct inspection of the ovaries. When given alone, megestrol acetate 5 mg. or Mestranol 0.1 mg. did not prevent ovulation in all cases.
  77. ^ Schacter L, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L (March 1989). "Megestrol acetate: clinical experience". Cancer Treat. Rev. 16 (1): 49–63. doi:10.1016/0305-7372(89)90004-2. PMID 2471590. At 0.25 mg/day MA has no apparent effect on the histology of the endometrium and is not effective as a contraceptive (53). However, at doses of 0.35 and 0.5 mg/day the drug is an effective contraceptive (10). At the 0.5 mg/day dose MA does not inhibit ovulation but does reduce sperm motility in post-coital tests (68).
  78. ^ Vessey, M.P.; Mears, Eleanor; Andolšek, Lidija; Ogrinc-Oven, Majda (1972). "Randomised double-blind trial of four oral progestagen-only contraceptives". The Lancet. 299 (7757): 915–922. doi:10.1016/S0140-6736(72)91492-4. ISSN 0140-6736.
  79. ^ Aufrère MB, Benson H (June 1976). "Progesterone: an overview and recent advances". J Pharm Sci. 65 (6): 783–800. doi:10.1002/jps.2600650602. PMID 945344. Early studies on its use as an oral contraceptive showed that, at 300 mg/day (5th to 25th day of the menstrual cycle), progesterone was effective in preventing ovulation through four cycles (263). The related effect of larger doses of progesterone on gonadotropin excretion also has been investigated. Rothchild (264) found that continuous or intermittent intravenously administered progesterone (100-400 mg/day) for 10 days depressed the total amount of gonadotropin excreted into the urine. However, Paulsen et al. (265) found that oral progesterone at 1000 mg/day for 87 days did not have a significant effect on urinary gonadotropin excretion. The efficacy of progesterone as an oral contraceptive was never fully tested, because synthetic progestational agents, which were orally effective, were available.
  80. ^ Pincus G (December 1958). "The hormonal control of ovulation and early development". Postgrad Med. 24 (6): 654–60. doi:10.1080/00325481.1958.11692305. PMID 13614060. Table 1: Effects of oral progesterone on three indexes of ovulation: Medication: Progesterone. Number: 69. Mean cycle length: 25.5 ± 0.59. Per cent positive for ovulation by: Basal temperature: 27. Endometrial biopsy: 18. Vaginal smear: 6. [...] we settled on 300 mg. per day [oral progersterone] as a significantly effective [ovulation inhibition] dosage, and this was administered from the fifth day through the twenty-fourth day of the menstrual cycle. [...] We observed each of 33 volunteer subjects during a control, nontreatment cycle and for one to three successive cycles of medication immediately following the control cycle. As indexes of the occurrence of ovulation, daily basal temperatures and vaginal smears were taken, and at the nineteenth to twenty-second day of the cycle an endometrial biopsy. [...] Although we thus demonstrated the ovulation-inhibiting activity of progesterone in normally ovulating women, oral progesterone medication had two disadvantages: ( l) the large daily dosage ( 300 mg.) which presumably would have to be even larger if one sought 100 per cent inhibition1 [...]
  81. ^ Pincus G (1956). "Some effects of progesterone and related compounds upon reproduction and early development in mammals". Acta Endocrinol Suppl (Copenh). 23 (Suppl 28): 18–36. doi:10.1530/acta.0.023S018. PMID 13394044.
  82. ^ Stone, Abraham; Kupperman, Herbert S. (1955). "The Effects of Progesterone on Ovulation: A Preliminary Report". The Fifth International Conference on Planned Parenthood: Theme, Overpopulation and Family Planning: Report of the Proceedings, 24-29 October, 1955, Tokyo, Japan. International Planned Parenthood Federation. p. 185.
  83. ^ S. Beier; B. Düsterberg; M. F. El Etreby; W. Elger; F. Neumann; Y. Nishino (1983). "Toxicology of Hormonal Fertility Regulating Agents". In Giuseppe Benagiano; Egon Diczfalusy (eds.). Endocrine Mechanisms in Fertility Regulation. Raven Press. pp. 261–346. ISBN 978-0-89004-464-3.
  84. ^ de Lignières B, Silberstein S (April 2000). "Pharmacodynamics of oestrogens and progestogens". Cephalalgia : an International Journal of Headache. 20 (3): 200–7. doi:10.1046/j.1468-2982.2000.00042.x. PMID 10997774.
  85. ^ a b Brady BM, Anderson RA, Kinniburgh D, Baird DT (April 2003). "Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male". Clinical Endocrinology. 58 (4): 506–12. doi:10.1046/j.1365-2265.2003.01751.x. PMID 12641635.
  86. ^ Wein, Alan J.; Kavoussi, Louis R.; Novick, Andrew C.; Partin, Alan W.; Peters, Craig A. (25 August 2011). Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set. Elsevier Health Sciences. pp. 2938–. ISBN 978-1-4160-6911-9. {{cite book}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
  87. ^ Kjeld JM, Puah CM, Kaufman B, Loizou S, Vlotides J, Gwee HM, Kahn F, Sood R, Joplin GF (1979). "Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men". Clinical Endocrinology. 11 (5): 497–504. doi:10.1111/j.1365-2265.1979.tb03102.x. PMID 519881.
  88. ^ Urotext (1 January 2001). Urotext-Luts: Urology. Urotext. pp. 71–. ISBN 978-1-903737-03-3.
  89. ^ Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R (1980). "Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial". Br J Urol. 52 (3): 208–15. doi:10.1111/j.1464-410x.1980.tb02961.x. PMID 7000222.
  90. ^ a b c J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 329–. ISBN 978-94-009-8195-9.
  91. ^ Bullock, Leslie P.; Bardin, C. W. (1977). "Androgenic, Synandrogenic, and Antiandrogenic Actions of Progestins". Annals of the New York Academy of Sciences. 286 (1 Biochemical A): 321–330. Bibcode:1977NYASA.286..321B. doi:10.1111/j.1749-6632.1977.tb29427.x. ISSN 0077-8923.
  92. ^ a b c Darney, Philip D. (1995). "The androgenicity of progestins". The American Journal of Medicine. 98 (1): S104–S110. doi:10.1016/S0002-9343(99)80067-9. ISSN 0002-9343.
  93. ^ Campagnoli, Carlo; Clavel-Chapelon, Françoise; Kaaks, Rudolf; Peris, Clementina; Berrino, Franco (2005). "Progestins and progesterone in hormone replacement therapy and the risk of breast cancer". The Journal of Steroid Biochemistry and Molecular Biology. 96 (2): 95–108. doi:10.1016/j.jsbmb.2005.02.014. ISSN 0960-0760. PMC 1974841. PMID 15908197.
  94. ^ Kenneth Hugdahl; René Westerhausen (2010). The Two Halves of the Brain: Information Processing in the Cerebral Hemispheres. MIT Press. pp. 272–. ISBN 978-0-262-01413-7.
  95. ^ a b c David A. Williams; William O. Foye; Thomas L. Lemke (January 2002). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 700–. ISBN 978-0-683-30737-5.
  96. ^ a b c Ricardo Azziz (8 November 2007). Androgen Excess Disorders in Women. Springer Science & Business Media. pp. 124–. ISBN 978-1-59745-179-6.
  97. ^ a b P. J. Bentley (1980). Endocrine Pharmacology: Physiological Basis and Therapeutic Applications. CUP Archive. pp. 4–. ISBN 978-0-521-22673-8.
  98. ^ Sengupta (1 January 2007). Gynaecology For Postgraduate And Practitioners. Elsevier India. pp. 137–. ISBN 978-81-312-0436-8.
  99. ^ Ferin, J. (1962). "Artificial Induction of Hypoestrogenic Amenorrhea with Methylestrenolone, or with Lynestrenol". European Journal of Endocrinology. 39 (1): 47–67. doi:10.1530/acta.0.0390047. ISSN 0804-4643.
  100. ^ Saunders, Francis J.; Drill, Victor A. (1956). "The Myotrophic and Androgenic Effects of 17-Ethyl-19-nortestosterone and Related Compounds". Endocrinology. 58 (5): 567–572. doi:10.1210/endo-58-5-567. ISSN 0013-7227. PMID 13317831.
  101. ^ a b c Armen H. Tashjian; Ehrin J. Armstrong (21 July 2011). Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Lippincott Williams & Wilkins. pp. 523–. ISBN 978-1-4511-1805-6.
  102. ^ de Gooyer, Marcel E; Deckers, Godefrides H; Schoonen, Willem G.E.J; Verheul, Herman A.M; Kloosterboer, Helenius J (2003). "Receptor profiling and endocrine interactions of tibolone". Steroids. 68 (1): 21–30. doi:10.1016/S0039-128X(02)00112-5. ISSN 0039-128X. PMID 12475720. [Norethisterone] has similar and [norethynodrel] weaker androgenic effects compared to tibolone.
  103. ^ Raynaud JP, Ojasoo T (1986). "The design and use of sex-steroid antagonists". J. Steroid Biochem. 25 (5B): 811–33. PMID 3543501. Similar androgenic potential is inherent to norethisterone and its prodrugs (norethisterone acetate, ethynodiol diacetate, lynestrenol, norethynodrel, quingestanol).
  104. ^ a b Chaudhuri (1 January 2007). Practice Of Fertility Control: A Comprehensive Manual (7Th Edition). Elsevier India. pp. 122–. ISBN 978-81-312-1150-2.
  105. ^ Kuhl H (1996). "Comparative pharmacology of newer progestogens". Drugs. 51 (2): 188–215. doi:10.2165/00003495-199651020-00002. PMID 8808163.
  106. ^ Stefan Offermanns; Walter Rosenthal (14 August 2008). Encyclopedia of Molecular Pharmacology. Springer Science & Business Media. pp. 391–. ISBN 978-3-540-38916-3.
  107. ^ a b Lara Marks (2001). Sexual Chemistry: A History of the Contraceptive Pill. Yale University Press. pp. 73–75, 77–78. ISBN 978-0-300-08943-1.
  108. ^ KORN GW (1961). "The use of norethynodrel (enovid) in clinical practice". Can Med Assoc J. 84: 584–7. PMC 1939348. PMID 13753182. Pseudohermaphroditism should not be a problem in these patients as it appears that norethynodrel does not possess androgenic properties, but it is believed that Wilkins has now found one such case in a patient who has been on norethynodrel therapy.
  109. ^ de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ (2003). "Receptor profiling and endocrine interactions of tibolone". Steroids. 68 (1): 21–30. doi:10.1016/s0039-128x(02)00112-5. PMID 12475720.
  110. ^ Ruggieri, Pietro de; Matscher, Rodolfo; Lupo, Corrado; Spazzoli, Giacomo (1965). "Biological properties of 17α-vinyl-5(10)-estrene-17β-ol-3-one (norvinodrel) as a progestational and claudogenic compound". Steroids. 5 (1): 73–91. doi:10.1016/0039-128X(65)90133-9. ISSN 0039-128X.
  111. ^ J. A. Simpson; E. S. C. Weiner (1997). Oxford English Dictionary Additions Series. Clarendon Press. pp. 36–. ISBN 978-0-19-860027-5.
  112. ^ JUCKER (8 March 2013). Fortschritte der Arzneimittelforschung / Progress in Drug Research / Progrès des recherches pharmaceutiques. Birkhäuser. pp. 166–. ISBN 978-3-0348-7053-5.
  113. ^ a b Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1989. pp. 199–. ISBN 978-0-08-058368-6.
  114. ^ a b c Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–92. doi:10.2165/00003495-200363050-00003. PMID 12600226.
  115. ^ Schneider HP (2003). "Androgens and antiandrogens". Annals of the New York Academy of Sciences. 997: 292–306. Bibcode:2003NYASA.997..292S. doi:10.1196/annals.1290.033. PMID 14644837.
  116. ^ Botella, J.; Paris, J.; Lahlou, B. (1987). "The cellular mechanism of the antiandrogenic action of nomegestrol acetate, a new 19-nor progestagen, on the rat prostate". European Journal of Endocrinology. 115 (4): 544–550. doi:10.1530/acta.0.1150544. ISSN 0804-4643.
  117. ^ Wiegratz I, Kuhl H (2006). "Metabolic and clinical effects of progestogens". Eur J Contracept Reprod Health Care. 11 (3): 153–61. doi:10.1080/13625180600772741. PMID 17056444.
  118. ^ Hammerstein J (1990). "Prodrugs: advantage or disadvantage?". Am. J. Obstet. Gynecol. 163 (6 Pt 2): 2198–203. PMID 2256526.
  119. ^ a b Paulsen CA, Leach RB, Lanman J, Goldston N, Maddock WO, Heller CG (1962). "Inherent estrogenicity of norethindrone and norethynodrel: comparison with other synthetic progestins and progesterone". J. Clin. Endocrinol. Metab. 22: 1033–9. doi:10.1210/jcem-22-10-1033. PMID 13942007.
  120. ^ a b Neumann, F.; Duesterberg, B.; Laurent, H. (1988). "Development of Progestogens". Female Contraception: 129–140. doi:10.1007/978-3-642-73790-9_11.
  121. ^ a b Philip W. Harvey (28 March 1996). Adrenal in Toxicology: Target Organ and Modulator of Toxicity. CRC Press. pp. 284–. ISBN 978-0-7484-0330-1.
  122. ^ Alfred Cuschieri; George Hanna (20 January 2015). Essential Surgical Practice: Higher Surgical Training in General Surgery, Fifth Edition. CRC Press. pp. 899–. ISBN 978-1-4441-3763-7.
  123. ^ John A. Thomas (12 March 1997). Endocrine Toxicology, Second Edition. CRC Press. pp. 152–. ISBN 978-1-4398-1048-4.
  124. ^ Nick Panay; Paula Briggs; Gab Kovacs (20 August 2015). Managing the Menopause. Cambridge University Press. pp. 126–. ISBN 978-1-107-45182-7.
  125. ^ Meis, Paul J. (2005). "17 Hydroxyprogesterone for the Prevention of Preterm Delivery". Obstetrics & Gynecology. 105 (5, Part 1): 1128–1135. doi:10.1097/01.AOG.0000160432.95395.8f. ISSN 0029-7844. PMID 15863556.
  126. ^ Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  127. ^ Oelkers W (2002). "Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone". Eur J Contracept Reprod Health Care. 7 Suppl 3: 19–26, discussion 42–3. PMID 12659403.
  128. ^ Foidart JM, Faustmann T (2007). "Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen". Gynecol. Endocrinol. 23 (12): 692–9. doi:10.1080/09513590701582323. PMID 18075844.
  129. ^ Genazzani AR, Mannella P, Simoncini T (2007). "Drospirenone and its antialdosterone properties". Climacteric. 10 Suppl 1: 11–8. doi:10.1080/13697130601114891. PMID 17364593.
  130. ^ Palacios S, Foidart JM, Genazzani AR (2006). "Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism". Maturitas. 55 (4): 297–307. doi:10.1016/j.maturitas.2006.07.009. PMID 16949774.
  131. ^ Blanton MP, Xie Y, Dangott LJ, Cohen JB (February 1999). "The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface". Mol. Pharmacol. 55 (2): 269–78. PMID 9927618.
  132. ^ Inhoffen HH, Logemann W, Hohlweg W, Serini A (May 4, 1938). "Untersuchungen in der Sexualhormon-Reihe (Investigations in the sex hormone series)". Ber Dtsch Chem Ges. 71 (5): 1024–32. doi:10.1002/cber.19380710520.
  133. ^ a b c d Maisel, Albert Q. (1965). The Hormone Quest. New York: Random House. OCLC 543168.
  134. ^ a b c Petrow V (1970). "The contraceptive progestagens". Chem Rev. 70 (6): 713–26. doi:10.1021/cr60268a004. PMID 4098492.
  135. ^ a b c Sneader, Walter (2005). "Hormone analogues". Drug discovery : a history. Hoboken, NJ: John Wiley & Sons. pp. 188–225. ISBN 0-471-89980-1.
  136. ^ a b c Djerassi C (2006). "Chemical birth of the pill". Am J Obstet Gynecol. 194 (1): 290–8. doi:10.1016/j.ajog.2005.06.010. PMID 16389046.
  137. ^ Djerassi C, Miramontes L, Rosenkranz G, Sondheimer F (1954). "Steroids. LIV. Synthesis of 19-Nor-17α-ethynyltestosterone and 19-Nor-17α-methyltestosterone" (PDF). J Am Chem Soc. 76 (16): 4089–91. doi:10.1021/ja01645a009.
  138. ^ Colton FB (1992). "Steroids and "the pill": early steroid research at Searle". Steroids. 57 (12): 624–30. doi:10.1016/0039-128X(92)90015-2. PMID 1481226.
  139. ^ a b c John L. McGuire (2000). Pharmaceuticals, 4 Volume Set. Wiley. p. 1580,1599. ISBN 978-3-527-29874-7.
  140. ^ A. Labhart (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 571–. ISBN 978-3-642-96158-8.
  141. ^ Bhasker Rao (1 January 1998). Clinical Gynecology (4Th Edition). Orient Blackswan. pp. 163–. ISBN 978-81-250-1622-9.
  142. ^ Annetine Gelijns (1991). Innovation in Clinical Practice: The Dynamics of Medical Technology Development. National Academies. pp. 167–. NAP:13513.
  143. ^ Robert W. Blum (22 October 2013). Adolescent Health Care: Clinical Issues. Elsevier Science. pp. 216–. ISBN 978-1-4832-7738-7.
  144. ^ Andrea Tone; Elizabeth Siegel Watkins (8 January 2007). Medicating Modern America: Prescription Drugs in History. NYU Press. pp. 117–119. ISBN 978-0-8147-8301-6.
  145. ^ C. Coutifaris; L. Mastroianni (15 August 1997). New Horizons in Reproductive Medicine. CRC Press. pp. 101–. ISBN 978-1-85070-793-6.
  146. ^ Shio Kumar Singh (4 September 2015). Mammalian Endocrinology and Male Reproductive Biology. CRC Press. pp. 270–. ISBN 978-1-4987-2736-5.
  147. ^ Frick, J. (1973). "Control of spermatogenesis in men by combined administration of progestin and androgen". Contraception. 8 (3): 191–206. doi:10.1016/0010-7824(73)90030-9. ISSN 0010-7824.
  148. ^ Nieschlag E, Kumar N, Sitruk-Ware R (2013). "7α-methyl-19-nortestosterone (MENTR): the population council's contribution to research on male contraception and treatment of hypogonadism". Contraception. 87 (3): 288–95. doi:10.1016/j.contraception.2012.08.036. PMID 23063338.
  149. ^ Attardi BJ, Hild SA, Reel JR (2006). "Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity". Endocrinology. 147 (6): 3016–26. doi:10.1210/en.2005-1524. PMID 16497801.

Further reading


Retrieved from "https://en.wikipedia.org/w/index.php?title=Progestogen_(medication)&oldid=857624412"